Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-MG: CABA-201 in Generalized Myasthenia Gravis
NCT06359041Phase 2Recruiting
- Sponsor
- Cabaletta Bio
- Start
- Dec 2024
- Primary completion
- Sep 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of resecabtagene autoleucel in myasthenia gravis (MG), sponsored by Cabaletta Bio. Started Dec 2024; status: recruiting.
02
Drugs
resecabtagene autoleucel
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06359041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359041.